Latest news

Debiopharm Group regains the commercial rights to Trelstar® (Triptorelin pamoate) and looks for new partners in North America

Grand succès du 3e Challenge pour la Qualité de vie des patients

GenePOC® launches its GenePOC® CDiff test in Canada

Debiopharm International SA and the Paul Scherrer Institute announce a licensing agreement for the development of a novel targeted radiotherapeutic…

The Japanese Cancer Association and Debiopharm Group Announce Winners of the 2018 JCA-Mauvernay Award

Le Challenge Debiopharm-Inartis récompense ses cinq finalistes 2018

Debiopharm Investment, BNP Paribas Développement, Bpifrance et Tikehau Capital accompagnent la croissance du groupe Carbonex

FDA Grants Fast Track designation to Debiopharm International’s Debio 1347 for the treatment of patients with unresectable or metastatic tumors…

Kaiku Health raises €4.4 million series A financing to accelerate its digital therapeutics pipeline led by Debiopharm and Tesi